Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Umeå researchers uncover new ALS gene

17.12.2007
The ALS research team at Umeå University in Sweden, working with Dutch and Belgian colleagues, has found new connections between mutations in gene DPP6 and contracting the non-hereditary form of ALS. The findings are being published in this Sunday's edition of Nature Genetics on the Web.

To try to identify pathological genes that are involved in ALS, the research group at Umeå University, in collaboration with Dutch and Belgian scientists, compared DNA samples from 1,767 patients with non-familial ALS (so-called sporadic ALS, SALS) with DNA samples from 1,916 control individuals. This is the world's most comprehensive ALS study so far. They looked for DNA mutations that only exist in ALS patients, not in controls. After very extensive analyses they found that a DNA mutation in the gene DPP6 strongly correlates with SALS.

The DPP6 gene is on chromosome number 7 and codes for a protein enzyme, a peptidase that regulates the activity of so-called neuropeptides, that is, substances that affect nerve cells. DPP6 is therefore highly interesting as a candidate gene for ALS. Studies are now concentrating on finding disease-associated mutations in the gene. Just how mutations in the DPP6 gene can lead to ALS is unknown today. At present it is not possible to judge whether the discovery will lead to any new treatment for ALS.

The Swedish component of the study was carried out by Associate Professor Peter M. Andersen, molecular geneticist Anna Birve, and research engineer Ann-Charloth Nilsson, all with the Department of Pharmacology and Clinical Neuroscience, Umeå University.

... more about:
»DNA »DPP6 »Umeå

Extensive research on ALS has been pursued at Umeå University since 1992. The objective is to use new knowledge about the mechanisms behind the disease in order to develop therapies for ALS. The main focus is on molecular biological and genetic aspects of the disease and mutations in SOD1 and other genes. Resources (funding, staffing) do not allow any attempted treatment of patients at present.

The research team at Umeå consists of 23 people in four subgroups, directed by Associate Professor Peter Andersen (genetic research), Associate Professor Thomas Brännström (neuropathology), Professor Stefan Marklund (free radicals and cell research), and Associate Professor Henrik Antti (metabolomics).

Contacts:
Anna Birve, post-doctoral fellow, at phone: +46 (0)90-785 29 47 or e-mail: anna.birve@neuro.umu.se.
Associate Professor Peter M. Andersen, phone: +46 (0)90-785 00 00 (exchange,
please page) or e-mail: peter.andersen@neuro.umu.se.
References: Michael A van Es, Paul WJ van Vught, Hylke M Blauw, Lude
Franke, Christiaan GJ Saris, Ludo Van Den Bosch, Sonja W de Jong,
Vianney de Jong, Frank Baas, Ruben van 't Slot, Robin Lemmens,
Helenius J Schelhaas, Anna Birve, Kristel Sleegers, Christine Van
Broeckhoven, Jennifer C Schymick, Bryan J Traynor, John HJ Wokke,
Cisca Wijmenga, Wim Robberecht, Peter M Andersen, Jan H Veldink, Roel
A Ophoff, & Leonard H. van den Berg:
Genetic variation in DPP6 is associated with susceptibility to
amyotrophic lateral sclerosis
Facts about ALS
The cause of the disease is unknown, but c. 10-12% of cases involve one of several hereditary variants of the disorder. In Sweden 200-220 people contract the illness each year. People of various ages are afflicted. The most common age is 50-70 years. Twice as many men as women suffer from the disorder.

The average survival time is 2.5-3 years, but some few patients live >10 years with the disease. There is no curative treatment. As of 1996 there is a medicine that slows down the course of the disease and can extend survival by a few months.

The effect is greatest if the medicine is introduced at an early stage of the illness. Nowadays there are special ALS teams that work to provide patients and their loved ones with the best possible help.

Bertil Born | idw
Further information:
http://www.nature.com/ng/index.html
http://www.umu.se/medfak/forskning/popvet/ALS.html

Further reports about: DNA DPP6 Umeå

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>